頁籤選單縮合
題名 | 綜述DPP-4抑制劑=Overviews of Dipeptidyl Peptidase-4 Inhibitors |
---|---|
作者 | 劉昭韓; 葉明功; 王春玉; Liu, Chao-han; Yeh, Ming-kung; Wang, Chun-yu; |
期刊 | 藥學雜誌 |
出版日期 | 20131200 |
卷期 | 29:4=117 2013.12[民102.12] |
頁次 | 頁22-27 |
分類號 | 418.271 |
語文 | chi |
關鍵詞 | 類昇糖素胜肽-1型類似物; 雙基胜肽酶-4型抑制劑; 第二型糖尿病; GLP-1 analog; DPP-4 inhibitor; Type 2 diabetes mellitus; |
中文摘要 | 近年來台灣因社會型態及飲食文化的改變,各種慢性疾病的人口發生率日益增加,常見的慢性疾病,例如:高血壓、糖尿病等等。其中糖尿病的發生率及盛行率正在快速的增加中,推估至 2050年全球糖尿病罹病人數將會上升至 5億人。台灣地區第二型糖尿病的盛行率亦呈現增加的趨勢,且死亡率始終高居十大死亡原因的前五名之一。 ADA/EASD糖尿病治療指引指出,嚴格控制血糖能有效延緩小血管或大血管併發症的發生。傳統的口服降血糖藥,主要的作用機轉在於刺激胰臟β細胞分泌胰島素。隨著糖尿病病程的進展,β細胞功能與數量會逐漸下降,降血糖藥的臨床效果也會越來越差。傳統口服降血糖藥的副作用包括低血糖、體重增加等。其中低血糖對病人有相當的危險性,體重增加可能是病人的服藥順從性不佳的原因之一;常見的副作用可能使病人用藥時達不到完整療效。因而新一代降血糖藥雙基胜肽酶抑制劑 (Dipeptidyl peptidase 4,簡稱 DPP-4 inhibitor),成為糖尿病治療的新趨勢,希望能藉此改善傳統口服降血糖藥的使用瓶頸。 |
英文摘要 | Because of the changes in social and dietary style, the incidence of chronic diseases such as hypertension and diabetes is getting more and more. The incidence and prevalence of diabetes mellitus increased rapidly. It is estimated that the number of patients suffering diabetes would be up to 500 millions by 2050. The prevalence of type 2 diabetes mellitus has also increased in Taiwan and the mortality rate was among the top five leading causes of death. According to the guideline of American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD), rigorous control of blood sugar should be performed to prevent early development of microvascular or macrovascular complications. Traditional oral hypoglycemic agents enhance insulin secretion from pancreatic β cells. Numbers and functions of β cells would decrease as progression of diabetes, and also the clinical effect. The side effects of these traditional drugs are hypoglycemia, weight gain... etc. Hypoglycemia would be relatively dangerous to patient. Weight gain might be one of the causes of poor compliance for the patient, all of them could cause inappropriate effect of medication, therefore newly development of DPP-4 inhibitors became great interesting and many clinical trials were ongoing. This article is to discuss about DPP-4. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。